Dynavax Technologies Corporation

NASDAQ:DVAX

11.17 (USD) • At close July 30, 2025
Bedrijfsnaam Dynavax Technologies Corporation
Symbool DVAX
Munteenheid USD
Prijs 11.17
Beurswaarde 1,341,304,770
Dividendpercentage 0%
52-weken bereik 9.22 - 14.63
Industrie Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Mr. Ryan Spencer
Website https://www.dynavax.com

An error occurred while fetching data.

Over Dynavax Technologies Corporation

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

Vergelijkbare Aandelen

Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.

SUPN

33.56 USD

Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc.

XENE

30.77 USD

Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc.

TVTX

15.48 USD

Krystal Biotech, Inc. logo

Krystal Biotech, Inc.

KRYS

153.22 USD

ImmunityBio, Inc. logo

ImmunityBio, Inc.

IBRX

2.56 USD

Establishment Labs Holdings Inc. logo

Establishment Labs Holdings Inc.

ESTA

41.96 USD

Addus HomeCare Corporation logo

Addus HomeCare Corporation

ADUS

107.88 USD

Ligand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated

LGND

135.23 USD

Vaxcyte, Inc. logo

Vaxcyte, Inc.

PCVX

34.82 USD

ModivCare Inc. logo

ModivCare Inc.

MODV

3.04 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)